Investigating a protein fragment's role in diabetes and kidney disease
Role of proteolytic suPAR fragment in insulin dependent diabetes and kidney disease
This study is looking at how a certain piece of a protein might harm the kidneys and pancreas in people with diabetes, and by doing so, it hopes to find new ways to help treat kidney disease and diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-11167555 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein fragment, known as the D2D3 fragment of the soluble urokinase receptor (suPAR), contributes to kidney and pancreatic damage in individuals with diabetes. The study aims to explore the mechanisms by which this fragment causes injury to kidney cells and insulin-producing cells in the pancreas. By analyzing blood samples and conducting laboratory experiments, researchers hope to uncover the pathways involved in this dual organ injury, which could lead to new treatment strategies for chronic kidney disease and diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals over 21 years old who have been diagnosed with diabetes and are at risk for chronic kidney disease.
Not a fit: Patients who do not have diabetes or chronic kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients suffering from diabetes and chronic kidney disease.
How similar studies have performed: Previous research has indicated that targeting biomarkers like suPAR can lead to significant insights in kidney disease, suggesting potential for success in this novel approach.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Sever, Sanja — University of Texas Med Br Galveston
- Study coordinator: Sever, Sanja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.